Agios Pharmaceuticals Inc AGIO:NASDAQ

Last Price$32.66NASDAQ Previous Close - Last Trade as of 4:00PM ET 12/06/21

Today's Change-1.56(4.56%)
Bid (Size)$27.00 (1)
Ask (Size)$40.43 (1)
Day Low / High$32.02 - 34.04
Volume829.5 K

View Biotechnology IndustryPeer Comparison as of 12/06/2021


Agios Pharmaceuticals Inc ( NASDAQ )

Price: $32.66
Change: -1.56 (4.56%)
Volume: 829.5 K
4:00PM ET 12/06/2021

Morphic Holding Inc ( NASDAQ )

Price: $47.72
Change: +3.51 (7.94%)
Volume: 166.7 K
4:00PM ET 12/06/2021

NanoString Technologies Inc ( NASDAQ )

Price: $38.05
Change: +0.70 (1.87%)
Volume: 495.4 K
4:00PM ET 12/06/2021

Global Blood Therapeutics Inc ( NASDAQ )

Price: $28.17
Change: +0.71 (2.59%)
Volume: 776.0 K
4:00PM ET 12/06/2021

Avid Bioservices Inc ( NASDAQ )

Price: $28.18
Change: -0.73 (2.53%)
Volume: 664.2 K
4:00PM ET 12/06/2021

Read more news Recent News

BofA Securities Starts Agios Pharmaceuticals at Buy With $54 Price Target
6:12AM ET 12/03/2021 MT Newswires

Agios Pharmaceuticals (AGIO) has an average rating of outperform and price targets ranging from $37 to $95, according to analysts polled by Capital IQ. (MT...

--HC Wainwright Adjusts Agios Pharmaceuticals' Price Target to $95 from $93, Keeps Buy Rating
12:33PM ET 11/04/2021 MT Newswires

(MT Newswires covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may...

Agios Pharmaceuticals Q3 Net Loss Per Share Widens
8:26AM ET 11/03/2021 MT Newswires

Agios Pharmaceuticals (AGIO) reported a Q3 net loss Wednesday of $1.56 per share, widening from a loss of $1.43 per share a year earlier. Analysts polled...

Agios Says US FDA Accepts Mitapivat New Drug Application for Priority Review
4:15PM ET 8/17/2021 MT Newswires

Agios Pharmaceuticals (AGIO) said Tuesday the US Food and Drug Administration accepted its new drug application for mitapivat in the treatment of pyruvate...

Company Profile

Business DescriptionAgios Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the discovery and development of novel investigational medicines to treat cancer and rare genetic diseases. It focuses on diseases that are directly caused by changes in genes or chromosomes, often passed from one generation to the next. The company was founded by Lewis Clayton Cantley, Tak W. Mak, Craig B. Thompson and Shin-Shan Michael Su on August 7, 2007 and is headquartered in Cambridge, MA. View company web site for more details
Address88 Sidney Street
Cambridge, Massachusetts 02139-4169
Number of Employees482
Recent SEC Filing11/03/20218-K
Chief Executive Officer & DirectorJacqualyn A. Fouse
CFO, Head-Legal & Corporate AffairsJonathan Prim Biller
Executive Vice President-Technical OperationsClive Patience
Chief Medical OfficerSarah Gheuens

Company Highlights

Price Open$34.04
Previous Close$32.66
52 Week Range$32.02 - 62.16
Market Capitalization$1.8 B
Shares Outstanding54.3 M
SectorHealth Technology
Next Earnings Announcement02/24/2022

Options Summary

Call Open Interest (1d)*
Put Open Interest (1d)*
Call Volume (1d)*
Put Volume (1d)*
Put Call Open Interest Ratio (1d)*
Put Call Volume Ratio (1d)*
* Data delayed by up to 15 minutes

View all fundamentalsFundamentals

Price / Earnings1.52
Earnings per Share-$6.02
Beta vs. S&P 500N/A
Revenue$94.4 M
Net Profit Margin-807.32%
Return on Equity-24.47%

Analyst Ratings as of 12/03/2021

Consensus RecommendationConsensus Icon
Powered by Factset